Material Weakness (removed) — Prior filing disclosed ongoing material weakness in internal controls (lack of segregation of duties, inadequate system/manual controls); current filing states controls are effective as of December 31, 2025.

NASDAQ: SILO Silo Pharma, Inc. 10-K

Silo Pharma pivots to crypto treasury, delays lead drug IND, terminates key MS license

Filed March 27, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 28, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade SILO commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 4, 2026 2:36 AM